Pierre Fabre Secures European Commission Approval for Braftovi Combination in BRAF-Mutant Colorectal Cancer
Pierre Fabre announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with...
Pierre Fabre
Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery
Pierre Fabre Laboratories announced a comprehensive drug discovery collaboration with French AI specialist Iktos to...
Pierre Fabre’s Braftovi Approved in China for BRAF V600E-mutant Metastatic Colorectal Cancer
France-based Pierre Fabre Laboratories announced that Braftovi (encorafenib) in combination with cetuximab has been approved...
Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics
France-based Pierre Fabre Laboratories announced the acquisition of global rights to PFL-721 and PFL-241 from...
Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology
France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG...
Pierre Fabre Partners with RedRidge Bio on BPA Drug Development for Oncology and Dermatology
France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge...
Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment
US-based Pfizer (NYSE: PFE) has announced receiving an indication extension approval from the US Food...
Scorpion Therapeutics and Pierre Fabre Collaborate on NSCLC Therapies STX-721 and STX-241
US-based Scorpion Therapeutics Inc. has formed a collaboration and license deal with France-based Pierre Fabre,...